Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is targeting the next wave of DNA damage response (DDR) cancer therapies, as highlighted in a recent BioMedWire editorial. The company is advancing ONC010, a nanoparticle-encapsulated PNKP inhibitor designed to target a DNA repair enzyme involved in multiple DNA repair pathways. This comes as the DDR inhibitor market rapidly expands beyond established PARP inhibitors, with new drug classes emerging.
According to the editorial, Onco-Innovations holds exclusive global rights to a foundational portfolio of PNKP inhibitor technology. This positions the company as an early leader in a novel class of cancer therapeutics. The potential impact of this technology is significant, as PNKP plays a critical role in DNA repair, and inhibiting it could enhance the effectiveness of existing cancer treatments like chemotherapy and radiation.
Preclinical data shows that ONC010 more than doubled median survival in PTEN-deficient colorectal cancer animal models while demonstrating a favorable toxicity profile. This suggests a promising therapeutic window for the drug candidate. The company is also progressing in manufacturing scale-up, IND-enabling studies, and plans for first-in-human clinical development. These efforts are supported by its proprietary SynoGraph causal AI platform through subsidiary Inka Health, which could accelerate drug development and identify optimal patient populations.
The DDR inhibitor market has seen significant activity, with major players like AstraZeneca plc (NYSE: AZN) developing PARP inhibitors for various cancers. However, resistance to PARP inhibitors remains a challenge, driving interest in alternative targets like PNKP. Onco-Innovations' approach could offer new treatment options for patients with tumors that are resistant to current therapies.
The editorial also reviewed recent developments in the oncology and biotechnology sectors involving Aprea Therapeutics Inc. (NASDAQ: APRE), Boundless Bio Inc. (NASDAQ: BOLD), and Foghorn Therapeutics Inc. (NASDAQ: FHTX). These companies are exploring various DDR and chromatin remodeling targets, highlighting the growing interest in this field.
For investors, the news underscores the potential of Onco-Innovations' technology. The company's exclusive license to patented technology targeting solid tumors provides a strong intellectual property position. As the company advances toward clinical trials, successful development could lead to a new class of cancer therapies with significant market potential. However, risks remain, including regulatory hurdles and the need for further clinical validation.
To view the full press release, visit https://ibn.fm/HH1VP. The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF.
